- Home
- OVID vs CNTB Comparison
OVID vs CNTB Comparison
Compare OVID & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OVID
- CNTB
- Stock Information
- Founded
- OVID 2014
- CNTB 2012
- Country
- OVID United States
- CNTB United States
- Employees
- OVID N/A
- CNTB N/A
- Industry
- OVID Biotechnology: Pharmaceutical Preparations
- CNTB Biotechnology: Pharmaceutical Preparations
- Sector
- OVID Health Care
- CNTB Health Care
- Exchange
- OVID Nasdaq
- CNTB Nasdaq
- Market Cap
- OVID 117.3M
- CNTB 93.9M
- IPO Year
- OVID 2017
- CNTB 2021
- Fundamental
- Price
- OVID $1.34
- CNTB $2.35
- Analyst Decision
- OVID Strong Buy
- CNTB Strong Buy
- Analyst Count
- OVID 4
- CNTB 3
- Target Price
- OVID $3.13
- CNTB $8.33
- AVG Volume (30 Days)
- OVID 1.5M
- CNTB 123.7K
- Earning Date
- OVID 11-12-2025
- CNTB 11-12-2025
- Dividend Yield
- OVID N/A
- CNTB N/A
- EPS Growth
- OVID N/A
- CNTB N/A
- EPS
- OVID N/A
- CNTB N/A
- Revenue
- OVID $6,610,000.00
- CNTB $762,000.00
- Revenue This Year
- OVID $1,081.80
- CNTB N/A
- Revenue Next Year
- OVID N/A
- CNTB $453,067.90
- P/E Ratio
- OVID N/A
- CNTB N/A
- Revenue Growth
- OVID 945.89
- CNTB N/A
- 52 Week Low
- OVID $0.24
- CNTB $1.23
- 52 Week High
- OVID $2.01
- CNTB $2.20
- Technical
- Relative Strength Index (RSI)
- OVID 46.30
- CNTB 74.38
- Support Level
- OVID $1.24
- CNTB $1.49
- Resistance Level
- OVID $1.39
- CNTB $1.74
- Average True Range (ATR)
- OVID 0.10
- CNTB 0.18
- MACD
- OVID -0.02
- CNTB 0.07
- Stochastic Oscillator
- OVID 45.94
- CNTB 93.84
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.